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ABSTRACT
Background: Buruli ulcer is a disease of the skin and soft tissues caused by infection
with a slow growing pathogen, Mycobacterium ulcerans. A vaccine for this disease is
not available but M. ulcerans possesses a giant plasmid pMUM001 that harbours
the polyketide synthase (PKS) genes encoding a multi-enzyme complex needed for
the production of its unique lipid toxin called mycolactone, which is central to the
pathogenesis of Buruli ulcer. We have studied the immunogenicity of enzymatic
domains in humans with M. ulcerans disease, their contacts, as well as non-endemic
areas controls.
Methods: Between March 2013 and August 2015, heparinized whole blood was
obtained from patients conﬁrmed with Buruli ulcer. The blood samples were diluted
1 in 10 in Roswell Park Memorial Institute (RPMI) medium and incubated for 5 days
with recombinant mycolactone PKS domains and mycolyltransferase antigen 85A
(Ag85A). Blood samples were obtained before and at completion of antibiotic
treatment for 8 weeks and again 8 weeks after completion of treatment. Supernatants
were assayed for interferon-g (IFN-g) and interleukin-5 (IL-5) by enzyme-linked
immunosorbent assay. Responses were compared with those of contacts and
non-endemic controls.
Results: More than 80% of patients and contacts from endemic areas produced
IFN-g in response to all the antigens except acyl carrier protein type 3 (ACP3) to
which only 47% of active Buruli ulcer cases and 71% of contacts responded. The
highest proportion of responders in cases and contacts was to load module
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ketosynthase domain (Ksalt) (100%) and enoylreductase (100%). Lower IL-5
responses were induced in a smaller proportion of patients ranging from 54% after
ketoreductase type B stimulation to only 21% with ketosynthase type C (KS C).
Among endemic area contacts, the, highest proportion was 73% responding to KS C
and the lowest was 40% responding to acyltransferase with acetate speciﬁcity type 2.
Contacts of Buruli ulcer patients produced signiﬁcantly higher IFN-g and IL-5
responses compared with those of patients to PKS domain antigens and to
mycolyltransferase Ag85A of M. ulcerans. There was low or no response to all the
antigens in non-endemic areas controls. IFN-g and IL-5 responses of patients
improved after treatment when compared to baseline results.
Discussion: The major response to PKS antigen stimulation was IFN-g and the
strongest responses were observed in healthy contacts of patients living in areas
endemic for Buruli ulcer. Patients elicited lower responses than healthy contacts,
possibly due to the immunosuppressive effect of mycolactone, but the responses were
enhanced after antibiotic treatment. A vaccine made up of the most immunogenic
PKS domains combined with the mycolyltransferase Ag85A warrants further
investigation.
Subjects Microbiology, Immunology, Infectious Diseases
Keywords Mycobacterium ulcerans, Immune response, Polyketide synthase domains, Buruli ulcer
INTRODUCTION
Buruli ulcer is a disease of the skin and soft tissues caused by infection with a slow growing
pathogen, Mycobacterium ulcerans (Demangel, Stinear & Cole, 2009). A large proportion
of the cases are reported by 33 countries from tropical, subtropical and temperate
climates in Africa, South America and the Western paciﬁc regions respectively (WHO,
2015). Globally, 5,000–6,000 cases are reported annually from 15 out of 33 countries
(WHO, 2015). Children between the age of 5 and 15 years account for 48% of African cases
but only 10% from Australia, and 19% from Japan (WHO). The majority of cases reported
from sub-Saharan Africa are from poor rural communities. The disease usually manifests
as a painless nodule, a ﬁrm plaque, or an ulcer with characteristic undermined edges and
more severe lesions may be associated with surrounding oedema (WHO, 2015). Treatment
has shifted from surgery to antibiotic therapy with the combination of oral rifampicin and
either intramuscular streptomycin or oral clarithromycin for 56 days. Although there is a
strong association with living near stagnant or slow ﬂowing water bodies, the mode of
transmission of the infection remains unknown (Portaels et al., 1999; Merritt et al., 2010;
Marion et al., 2010) and development of a protective vaccine is highly desirable.
Currently, there is no vaccine for M. ulcerans disease. In early studies M. bovis BCG
vaccine appeared to be protective for 6 months after vaccination but thereafter its
effect waned. However, these ﬁndings were not conclusive because the disease incidence
declined in the study area (Smith et al., 1976; Uganda Buruli Group, 1969; Huygen, 2003;
Nackers et al., 2006; Portaels et al., 2004; Tanghe et al., 2007). Recently a retrospective
study failed to demonstrate any protection associated with the presence of BCG scars and
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there was no apparent protection from the severe forms of disease (Phillips et al., 2015).
However, evidence has been presented that BCG protects against the osteomyelitis
complicating M. ulcerans infection. A study looking at the protective efﬁcacy of a DNA
vaccine encoding antigen 85A (Ag85A) from M. bovis BCG showed that it could
signiﬁcantly reduce the bacterial load in footpads of mice challenged with M. ulcerans
(Tanghe et al., 2001). DNA vaccination with M. ulcerans heat shock protein-65 (HSP-65)
also conferred some protection against M. ulcerans in mice (Coutanceau et al., 2006)
but although HSP-65 protein was immunogenic, it may not be a good vaccine candidate
since it shares homology with human HSP-60.
Mycobacterium ulcerans possesses a giant plasmid PMUM001 that encodes
polyketide synthases (PKSs) needed for the production of its unique lipid toxin called
mycolactone (Stinear et al., 2004; Porter et al., 2013). This macrolide toxin is central to
the pathogenesis of Buruli ulcer and it has cytotoxic and immunosuppressive properties
but it is poorly immunogenic. Therefore, in the efforts to develop a vaccine, one approach
has been to target the enzymatic domains that play a key role in synthesis of mycolactone
(Porter et al., 2013). A recent study in mice showed that E. coli derived recombinant
proteins generated by plasmid DNA encoding mycolactone PKS domains were
immunogenic providing modest protection (Roupie et al., 2014).
In this study, IFN-g was selected as a T-helper 1 (Th1) marker while Interleukin-5
(IL-5) was measured for T-helper 2 (Th2) responses. The best defence against
mycobacterial infections is driven by the production of IFN-g by helper T-cells. Activated
IFN-g can increase the ability of macrophages to kill intracellular mycobacteria by nitric
oxide induced apoptosis (Bibert et al., 2017). IL-5 is a cytokine that acts as a growth
and differentiation factor for both B-cells and eosinophils. The encoded cytokine plays a
major in the regulation of eosinophils formation, maturation, recruitment and survival
(Clutterbuck, Hirst & Sanderson, 1989; Sanderson, 1992).
The aim of the present study was to understand the immunogenicity of similar
antigens in humans with M. ulcerans disease and their contacts as well as in control
participants from non-endemic areas by the induction of antigen speciﬁc cellular
immune response.
MATERIALS AND METHODS
Study participants and design
Between March 2013 and August 2015, consecutive patients with clinically suspected
Buruli ulcer presenting at clinics in Agogo Presbyterian Hospital in the Ashanti-Akim-
North district, Tepa Government Hospital in the Ahafo-Ano-district, Nkawie-Toase
Government Hospital of the Atwima Nwabiagya district in the Ashanti Region and
Dunkwa Government Hospital in the Upper Denkyira East district in the Central Region
of Ghana, were asked to participate in the study. Concurrently, age matched contacts of
patients from the endemic districts and non-endemic controls living in Kumasi where
Buruli ulcer is not endemic were recruited. Patients and controls were only recruited
after oral and written consent had been secured. Patients were enrolled if they met the
WHO clinical case deﬁnition ofM. ulcerans disease (WHO, 2015) and were included if the
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clinical diagnosis of M. ulcerans disease was subsequently conﬁrmed by a positive
IS2404 PCR.
Patients were excluded when they were aged below 5 years, were unwilling to give
informed consent or already on treatment. Ethical approval for this study was obtained
from the Committee on Human Research, Publications and Ethics (CHRPE/AP/229/12),
School of Medical Sciences, Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana. An endemic control or contact was an age matched healthy
relative, spouse or neighbour permanently residing in the same community.
Endemic controls were veriﬁed to have no past or current diagnosis of Buruli ulcer.
Participants who did not visit or reside in a Buruli endemic area were considered
as non-endemic controls.
For patients with Buruli ulcer, basic demographic data including age, sex, lesion
form, lesion site and category were recorded on standard WHO BU01 forms (WHO,
2018). Swabs from ulcers and ﬁne needle aspirates from pre-ulcerative lesions were
obtained forM. ulcerans IS2404 PCR and also combined with theM. ulcerans 16S rRNA as
previously described (Phillips et al., 2009; Sarpong-Duah et al., 2017; Sarfo et al., 2010).
Patients were treated with combination oral rifampicin 10 mg/kg and intramuscular
streptomycin 15 mg/kg daily for 8 weeks or oral clarithromycin. This was administered
at village health posts under direct observation with fortnightly visits to participating
hospitals for clinical review and assessment of compliance to antibiotic therapy.
After antibiotic therapy patients were followed up monthly for one year.
Heparinized blood samples were obtained for immune response assessment before
and at completion of antibiotic treatment at week 8 and again 8 weeks after completion
of treatment.
Antigens
Bacterial expression vectors pET-DEST42, encoding the genes of 11 mycolactone PKS
domains, namely, acyl carrier protein (ACP) types 2 and 3, acyltransferase with acetate
speciﬁcity type 1 and 2 (ATac1, ATac2), acyltransferase with propionate speciﬁcity (ATp),
enoylreductase (ER), ketoreductase type A and B (KR A, KR B), ketosynthase type C (KS C),
load module ketosynthase domain (Ksalt) and dehydratase (DH), (all as C-terminally
Histidine-tagged proteins), were constructed at the University of Melbourne, Australia, sent
to Brussels and used for transformation and selection in E. coli BL-21. Following induction
with Isopropyl-b-D-thioglactopyranoside (IPTG) for 2–4 h, cells were lysed and
recombinant proteins were puriﬁed according to standard protocol on immobilized metal
afﬁnity chromatography using gravity ﬂow. Recombinant Ag85A protein from M. ulcerans
(MUL 4987) was kindly given to us by Dr. G. Pluschke (Swiss Tropical and Public Health
Institute, Basel, Switzerland) (Roupie et al., 2014). All antigens were used at a ﬁnal
concentration of ﬁve mg/ml based on experiences from an earlier study (Phillips et al., 2006).
Positive controls were one mg/ml phorbol 1-myristate 1-acetate plus ionomycin
(PMA + Io) and ﬁve mg/ml lipopolysaccharide (Sigma-Aldrich, Dorset, UK) while
medium alone was the negative control.
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Whole blood antigen stimulation
A total of six ml of venous blood was taken in sodium heparin Vacutainer tubes
(Becton Dickinson, Oxford, UK) at baseline, week 8 and week 16 and transported to the
laboratory for diluted whole assay within 2 h of sampling. The whole-blood assay was
performed as described previously (Sarfo et al., 2009). Brieﬂy, whole blood was diluted
1 in 10 in Roswell Park Memorial Institute medium supplemented with penicillin
(100 IU/ml) and streptomycin (100 g/ml) (Sigma-Aldrich, Darmstadt, Germany) in
sterile 50 ml Falcon tubes, mixed gently and distributed, one ml per well into 24-well
plates (Nunclon, Roskilde, Denmark). A total ﬁve mg/ml of PMA, recombinant ACP2,
ACP3, Atac1, Atac2, ATp, ER, KR A, KR B, KS C, Ksalt, DH, Ag85Aulc and no
stimulant was pipetted into each well, after which the culture plates were gently swirled
10 times clockwise and anticlockwise. Culture plates were incubated at 37 !C in 5% CO2
for 5 days. Supernatants (300–500 ml per well) were stored at -70 !C for interferon-g
(IFN-g) and IL-5 assays.
Enzyme linked immunosorbent assay
Human IFN-g and IL-5 concentrations were determined using OptEIA ELISA kits in
accordance with the protocol provided by manufacturer (BD Biosciences, Pharmingen,
San Diego, CA, USA). Optical densities at 450–620 nm were measured with an ELISA plate
reader (Sunrise Tecan, Salzburg, Austria) with xread plus version 4.30 software. IFN-g
recombinant cytokine (300 to 4.7 pg/ml; BD Biosciences, Pharmingen, San Diego, CA,
USA) was used for the standard curve. IL-5 recombinant cytokine (BD Biosciences,
Pharmingen, San Diego, CA, USA) was used for the standard curve. The lower detection
limits were 4.7 pg/ml for IFN-g and 7.8 pg/ml for IL-5. A positive cytokine measurement
in the unstimulated culture supernatants, if detected, was subtracted from measurements
in the test wells for IFN-g and IL-5. In the analysis, a cut off of 37 pg/ml was used for both
IFN-g and IL-5 to deﬁne a responder status since none of the subjects produced more
than 37 pg/ml in unstimulated cultures.
Combined 16S rRNA reverse transcriptase/IS2404 qPCR viability
assay
Fine needle aspirates and swab samples were transported from study site to the
KCCR stabilized in 500 ml RNA protect (Qiagen, Manchester, UK) for the M. ulcerans
combined 16S rRNA reverse transcriptase/IS2404 qPCR viability assay as described
elsewhere (Sarpong-Duah et al., 2017). Brieﬂy, whole transcriptome RNA and whole
genome DNA were extracted from the same clinical sample. The RNA and DNA isolation
was carried out using the AllPrep DNA/RNA Micro kit (Qiagen, Manchester, UK) as
previously described (Beissner et al., 2012; Sarpong-Duah et al., 2017). A total of 12 ml RNA
extracts were immediately reverse transcribed (Sarpong-Duah et al., 2017). The cDNA was
then subjected to 16S rRNA qPCR and DNA to IS2404 qPCR to increase the speciﬁcity for
M. ulcerans. Quantitative PCR of IS2404 (DNA), and 16S rRNA (cDNA) targets were
carried out at 95 !C for 15 min, and then 40 cycles of 95 !C for 15 s and 60 !C for 60 s
in a Bio-Rad CFX 96 real time PCR detection system (Bio-Rad, Singapore).
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Statistical analysis
Results were analysed with GraphPad Prism 6 software (GraphPad Software Inc., La Jolla,
CA, USA) and a standard (best-ﬁt) curve was plotted. Descriptive results of cytokines were
expressed as medians and ranges. Medians for participants at the various time points
of the study were compared using the Mann–Whitney U-test; P < 0.05 were considered
signiﬁcant. IFN-g responses of patients with positive 16S rRNA reverse transcriptase/
IS2404 qPCR signal suggestive of viable M. ulcerans at week 8 were noted.
RESULTS
Participant characteristics
Table 1 shows the characteristics of 24 participants with active Buruli ulcer disease,
30 endemic area patient contacts and 11 non-endemic area controls. Mean and standard
deviation (±SD) of age was 20 (±17) years for patients with active lesions, 21 (±13) years
for contacts and 24 (±4) years for controls from non-endemic regions. One-way
analysis of variance showed no signiﬁcant difference in the ages of the participants
(P = 0.6957). There were 11 patients with non-ulcerative forms (four nodules and
seven plaques) and 13 patients with ulcers.
IFN-g and IL-5 responses to 11 recombinant PKS domain antigens or
Ag85A in Buruli ulcer patients, contacts and non-endemic area
controls
Using a cut off of 37 pg/ml of IFN-g to deﬁne a responder status, more than 80% of
patients and contacts from endemic areas responded to all the antigens except ACP3 to
which only 47% of active Buruli ulcer cases and 71% of contacts responded. The highest
proportion of responders in both patients and endemic area controls was to Ksalt
(100%) and ER (100%). Overall, a higher proportion of contacts responded with
higher IFN-g responses than the Buruli ulcer cases to all the PKS domain antigens and
to DNA encoding mycolyltransferase Ag85A of M. ulcerans (Ag85Aulc). There was
low or no response to any of the antigens in all except one of the non-endemic area
controls (Fig. 1).
With a cut off of 37 pg/ml for IL-5, responses of cases and endemic controls were
modest compared to those for IFN-g. The highest proportion of responders among
BU cases was to KR B (54%) and the lowest to KS C (21%). Among endemic area
contacts the highest proportion was to KS C (73%) and the lowest to Atac2 (40%).
There were low or nil responses in non-endemic controls apart from 6/11 (55%)
responding to ER (Fig. 2).
Comparison of IFN-g and IL-5 responses between M. ulcerans disease
cases, healthy contacts and healthy non-endemic controls
When individual responses were compared, contacts of Buruli ulcer patients produced
signiﬁcantly higher IFN-g responses compared with those of patients for ATp
(median 3,416 vs 449 pg/ml), Ksalt (4,611 vs 521 pg/ml), ACP2 (3,794 vs 319 pg/ml),
KS C (3,945 vs 618 pg/ml), DH (median 4,596 vs 671 pg/ml), ER (5,024 vs 3,010 pg/ml),
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KR B (5,261 vs 1,004 pg/ml), Atac2 (4,900 vs 1,215 pg/ml) (P < 0.05). Despite a trend
to higher IFN-g responses in contacts compared with cases it did not reach signiﬁcance
for ATac1, ACP3, KR A and M. ulcerans Ag 85A (Fig. 3). Similarly, comparing IL-5
Figure 1 IFN-g responses to a panel of polyketide synthase domains in 5 day diluted whole blood
culture supernatants of M. ulcerans disease patients, healthy contacts and healthy non-endemic
controls. A cut off of 37 pg/ml of IFN-g was used to deﬁne responder status. Each bar represent
percentage (%) of responders of a participant group to a speciﬁc PKS domain antigen.
Full-size DOI: 10.7717/peerj.5294/ﬁg-1
Table 1 Characteristics of study participants.
Number of participants Active Buruli
ulcer n = 24
Contacts* n = 30 Non-endemic
controls** n = 11
Age
Mean (±SD) 20 (±17) 21 (±13) 24 (±4)
Sex
Male to female ratio 13:11 14:16 7:4
Lesion form (%)
Nodule 4 (17) N/A N/A
Plaque 7 (29) N/A N/A
Ulcer 13 (54) N/A N/A
Lesion category (%)
I 10 (42) N/A N/A
II 11 (46) N/A N/A
III 3 (12) N/A N/A
Notes:
N/A: not applicable. One-way analysis of variance test showed no differences in age distribution between the study
groups (P = 0.6957).
* Contacts: family members of Buruli ulcer patients living in the endemic area.
** Non-endemic controls were resident in Buruli ulcer non-endemic areas.
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responses (albeit low), contacts of Buruli ulcer patients produced signiﬁcantly higher IL-5
responses compared with those of patients for ATp (median 31 vs 12 pg/ml), KS C
(54 vs 20 pg/ml), Atac1 (57 vs 25 pg/ml), (P < 0.05). There were no signiﬁcantly higher
IL-5 responses in contacts compared with cases for KR B, DH, ACP2, ER, ACP3, KR A,
Atac2 or M. ulcerans Ag85A (Fig. 4).
There were no signiﬁcant differences in IFN-g and IL-5 responses when patients with
ulcerative disease were compared with those with non-ulcerated (earlier) forms of disease
(Figs. S1 and S2).
Comparison of IFN-g responses of Buruli ulcer patients before and
after treatment
Signiﬁcantly higher responses to recombinant antigens ACP2 and ATac2 (P < 0.05) were
observed after 8 weeks standard antibiotic treatment compared with those at baseline.
There was no signiﬁcant difference in response to the other candidate antigens before
and after 8 weeks treatment (Table 2). Responses to three of the most immunogenic
antigens were also tested at week 16, 8 weeks after completion of treatment and were
found to be signiﬁcantly higher for ATp (1,544 vs 363.6, P = 0.015), Ksalt (3,803 vs
521.2, P = 0.006) and ER (7,662 vs 3,010, P = 0.0003) than at baseline. Further, IFN-g
responses to ER at week 16 were signiﬁcantly higher than those at week 8 (7,662 vs 4,397,
P = 0.001) (Fig. 5).
There was no correlation between clinical form of disease, duration of lesion, category
of lesion, presence of BCG scar, time to healing and level of IFN-g responses to Ksalt
and ER antigen. However, patients with viable organisms at baseline and week 8 produced
Figure 2 IL-5 responses to a panel of polyketide synthase domains in 5 day diluted whole blood
culture supernatants of M. ulcerans disease patients, healthy contacts and healthy non-endemic
controls. A cut off of 37 pg/ml of IL-5 was used to deﬁne responder status. Each bar represent
percentage (%) of responders of a participant group to a speciﬁc PKS domain antigen.
Full-size DOI: 10.7717/peerj.5294/ﬁg-2
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Figure 3 IFN-g responses to a panel of polyketide synthase domain antigens in 5 day diluted whole blood culture supernatants of
Mycobacterium ulcerans disease patients, healthy endemic controls and healthy non-endemic controls. IFN-g responses are shown for ATp
(A), Ksalt (B), ACP2 (C), Ksc (D), DH (E), ER (F), KRA (G), Atac1 (H), Ag85Aulc (I), KRB (J), ACP3 (K) and Atac2 (L). Each dot represents the
response of one study participant. The horizontal lines represent the median and Interquartile range for each group. Medians for groups were
compared using Mann-Whitney U-test. Full-size DOI: 10.7717/peerj.5294/ﬁg-3
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Figure 4 IL-5 responses to a panel of polyketide synthase domain antigens in 5 day diluted whole blood culture supernatants of
Mycobacterium ulcerans disease patients, healthy endemic controls and healthy non-endemic controls. IFN-g responses are shown for ATp
(A), KSC (B), Atac1 (C), KRB (D), Ksalt (E), ACP2 (F), DH (G), KRA (H), Ag85Aulc (I), Atac2 (J), ER (K) and ACP3, (L). Each dot represents the
response of one study participant. The horizontal lines represent the median and Interquartile range for each group. Medians for groups were
compared using Mann-Whitney U-test. Full-size DOI: 10.7717/peerj.5294/ﬁg-4
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low IFN-g responses to Ksalt with the exception of one patient that made a good response
at week 8 (Fig. 6).
Signiﬁcantly higher IL-5 responses to recombinant antigens ATac1 and ATp
(P = 0.0129 and P = 0.0149 respectively) were observed after 8 weeks standard
antibiotic treatment. There was no signiﬁcant difference in response to the other PKS
antigens before and after 8 weeks treatment (Table 2). There was no correlation
between clinical form of disease, duration of lesion, category of lesion, time to healing
and level of IL-5 responses but patients with BCG scars had signiﬁcantly higher levels
for Ksalt (P = 0.0108) and ACP2 (P = 0.0160) compared to patients who had no
BCG scars (Figs. S3 and S4).
The three antigens that induced high IFN-g responses were tested also for IL-5
production at week 16, 8 weeks after completion of treatment. ATp stimulated signiﬁcantly
Table 2 IFN-g and IL-5 responses to a panel of PKS antigens and Antigen85A after diluted whole blood stimulation for 5 days of 24
Mycobacterium ulcerans disease cases.
Cytokines
[median(range) pg/ml)]
Antigens Week 0 Week 8 P-value‡ Week 16 P-value‡‡
Interferon-g ACP2 319.1 (0–6,939) 1,004 (13–6,584) 0.0462 ND
ACP3 33.55 (0–2,054) 1 (0–3,507) 0.3881 ND
ATac1 1,270 (0–7,753) 28,439 (226–8,776) 0.1108 ND
ATac2 1,215 (0–7,753) 4,973 (0–12,355) 0.0494 ND
ATp 449.4 (0–4,269) 770 (0–6,659) 0.2036 1,544 (61–11,066) 0.0294
ER 3,010 (0–8,855) 4,397 (38–9,064) 0.2808 7,662 (64–11,103) 0.0003
KR A 2,850 (0–8,797) 3,561 (4–11,288) 0.3887 ND
KR B 1,004 (0–7,299) 4,851 (25–10,745) 0.0568 ND
KS C 618.4 (0–7,277) 1,190 (25–8,101) 0.2725 ND
Ksalt 521.2 (0–7,764) 1,950 (37–8,173) 0.2166 3,803 (136–11,229) 0.0169
DH 671.2 (0–6,587) 2,037 (44–9,086) 0.077 ND
Ag85Aulc 307.4 (0–3,440) 2,287 (0–6,735) 0.0551 ND
Interleukin-5 ACP2 26.94 (0–125.1) 52.87 (0–178) 0.1013 ND
ACP3 24.19 (0–114.4) 45.46 (0–1,396) 0.2089 ND
ATac1 25.02 (0–179.5) 52.7 (0–286.2) 0.0129 ND
ATac2 23.22 (0–412.4) 47.46 (0–167.3) 0.9695 ND
ATp 12.4 (0–85.08) 42.55 (0–144.6) 0.0149 42.35 (5.59–1,071) 0.002
ER 39.14 (0–415.4) 58.82 (0–189.6) 0.105 39.47 (0–952.4) 0.2511
KR A 28.07 (0–1,401) 46.34 (0–124.5) 0.1039 ND
KR B 40.44 (0–245.3) 42.58 (0–148.5) 0.5197 ND
KS C 19.84 (0–294.6) 36.00 (0–149.7) 0.1284 ND
Ksalt 17.37 (0–140) 44.19 (0–151.5) 0.1937 43.51 (0–987.1) 0.1067
DH 20.98 (0–188.2) 28.17 (0–162) 0.4519 ND
Ag85Aulc 40.06 (0–676.7) 51.9 (0–614.9) 0.2236 ND
Notes:
ND, not done.
‡ Mann–Whitney test comparing baseline (week 0) IFN-g and IL-5 responses with those of with week 8.
‡‡ Mann–Whitney test comparing baseline (week 0) IFN-g and IL-5 responses with those of with week 16. P < 0.05 indicate a signiﬁcant difference.
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Figure 5 IFN-γ and IL-5 responses before (week 0), at completion of antibiotic treatment (week 8)
and 8 weeks after antibiotic completion (week 16) to polyketide synthase antigens. IFN-g responses
are shown for ATp (A), Ksalt (C) and ER (E) while IL-5 responses are shown for ATp (B), Ksalt (D) and
ER (E). Comparison between groups was done with Mann-Whitney test. Each dot represents the
response of one study participant. The horizontal lines represent the median and Interquartile range for
each group. Full-size DOI: 10.7717/peerj.5294/ﬁg-5
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higher IL-5 production [42.35 (5.59–1,071) P = 0.002] than at baseline but Ksalt and ER
yielded no signiﬁcant responses.
DISCUSSION
The immune response to M. ulcerans antigens observed in patients with Buruli ulcer and
their contacts may give an indication of the responses desirable to protect against the
disease. We have shown previously that whole blood IFN-g responses to M. ulcerans
sonicate were low in untreated patients but improved after treatment with antibiotics,
and also that signiﬁcant responses were mounted by contacts from endemic areas but
not by people from non-endemic areas (Phillips et al., 2006; Sarfo et al., 2009). A unique
characteristic of M. ulcerans is that it produces the toxin mycolactone which not only
causes the cell necrosis associated with ulcers but is also immunosuppressive at low
concentrations. Therefore, it is highly relevant to establish whether an immune response
can be mounted to mycolactone. The molecule itself is lipid-like, being formed of
a lactone ring and two polyketide side chains, so not surprisingly it is of low antigenicity
Figure 6 Comparison of IFN-g responses before (week 0), at completion (week 8) of antibiotics and
8 weeks after antibiotic completion (week 16) to plasmid DNA encoding mycolactone PKS antigens
Ksalt. Red dots represent IFN-g responses of patients with detection of viable organisms at week 8. Each
dot represent response for one study participant. The horizontal lines represent the median and
Interquartile range for each group. Full-size DOI: 10.7717/peerj.5294/ﬁg-6
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(Dangy et al., 2016). However, it has already been shown that an IgG antibody response
can be mounted to proteins generated by several PKS domains both in patients with Buruli
ulcer and in their close contacts (Pidot et al., 2010). In the present study, we have
investigated the cellular immune response to recombinant proteins representing
11 PKS enzymatic domains and to recombinant Ag85A of M. ulcerans in Buruli ulcer
patients and their healthy contacts as well as in people from non-endemic areas. All the
proteins tested induced IFN-g secretion in the whole blood stimulation assay, the strongest
response being associated with ER and Ksalt. IL-5 responses were more modest, and at
best only 54% of patients responded to KR B and 73% of contacts to KS C, suggesting
that the major type of response generated in vivo is TH-1. It is of considerable interest
that the highest responses were seen in contacts of patients rather than in patients
themselves. There are two possible explanations for this. The most likely explanation is
that ongoing mycolactone production suppresses the immune response of patients but a
predisposition to reduced immune responsiveness must also be considered. Against this is
the fact that IFN-g responses to ATp, Ksalt and ER improved signiﬁcantly after antibiotic
treatment for 8 weeks and, in the case of ER, had continued to increase after 16 weeks.
At non-cytotoxic concentrations, mycolactone displays immunomodulatory properties
on human primary monocytes and dendritic cells, indicating that the toxin may limit
the triggering of innate immune responses in vivo (Coutanceau et al., 2007; Simmonds
et al., 2009). By blocking the capacity of primary T-cells to produce multiple cytokines
upon activation and by impairing T-cell migration and homing into lymph nodes,
mycolactone can signiﬁcantly inhibit the development of the adaptive immune responses
to M. ulcerans (Boulkroun et al., 2010; Guenin-Mace et al., 2011). More recent evidence
has also revealed that mycolactone exerts a profound effect on protein secretion by
blocking the co-translational translation of a plethora of proteins such as TNF and IL-6 as
well as nearly all other proteins that pass through the endoplasmic reticulum for secretion
or placement in cell membranes (Hall & Simmonds, 2014; Ogbechi et al., 2015).
It has been hypothesized that a signiﬁcant proportion of the population residing in an
area of M. ulcerans endemicity may have been exposed to M. ulcerans without developing
disease (Gooding et al., 2002). Our results support this concept and may also give an
indication of the most important antigens for providing protection, ATp, Ksalt and ER
being possible candidates. This could be tested in an animal model and in earlier studies
it was found that mice vaccinated with ATp, ER and KRA showed a modest reduction
in bacterial load or prolonged survival following M. ulcerans challenge, albeit to a lower
extent than mice vaccinated with Ag85A orM. bovis BCG (Roupie et al., 2014). In another
model of mouse infection with M. ulcerans, IFN-g knockout mice displayed faster
disease progression compared to wild type mice (Bibert et al., 2017). This supports the
existing paradigm that IFN-g production by T-cells is a key marker for host defence
against this mycobacterial infection.
CONCLUSION
We have demonstrated strong human cytokine responses speciﬁc for PKS domains in
healthy contacts of Buruli ulcer patients, with lower responses in patients which improved
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after antibiotic treatment. ER and load module ketosynthase domain (Ksalt) were the most
immunogenic antigens for IFN-g responses, whereas KS C and KR B were the most
immunogenic for contacts and cases, respectively, with regard to IL-5 production.
A vaccine made up of the most immunogenic mycolactone PKS domains for TH-1
response (IFN-g) combined with the mycolyltransferase Ag85A warrants further study.
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